Answers are grounded in this paper and cite their sources.
Age-related macular degeneration (AMD) is one of the leading causes of central vision loss in older adults and is becoming an increasingly important health problem in aging populations. This disease involves complex interactions among oxidative stress, chronic inflammation, retinal pigment epithelium dysfunction, changes in Bruch’s membrane, complement system dysregulation, and genetic factors. Diagnostic advances in retinal imaging, particularly optical coherence tomography (OCT), and a better understanding of morphological and molecular biomarkers have expanded clinicians’ ability to recognize disease course, assess progression risk, and evaluate treatment response. From a therapeutic perspective, AMD management includes AREDS2-based nutritional supplementation in selected cases, anti-vascular endothelial growth factor (anti-VEGF) therapy for the neovascular form, and the development of new approaches such as gene therapy and long-term drug delivery systems. This review briefly discusses the diagnostic and therapeutic aspects of AMD to support evidence-based understanding and clinical practice. Early recognition and appropriate management are important for preserving vision and guiding patient care.
No takes yet. Share an insight, caveat, or question.
Digambiro et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: